We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Piracetam
First-ever nootropic (1972), with decades of safety data. Recent meta-analyses find no clear cognitive benefit, including in adults with memory impairment.
Research compound — not a dietary supplement
Piracetam is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Piracetam doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1976–2026 with a typical study size of 200 participants.
Based on 108 studies · 12 meta-analyses · 88 RCTs · 46,227 total participants
Confidence
High confidenceWhat the studies found
By outcome
Scores low/Emerging because despite decades of trials and a strong safety record, recent meta-analyses find no clinically significant cognitive benefit in healthy adults, with positive signals confined to clinical populations.
91 randomised trials
84% were about Piracetam in an audit of 50 of them
Every randomised or controlled trial of Piracetam indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
3 trials ongoing or recruiting · 7 completed on ClinicalTrials.gov
Registered trials show research momentum for Piracetam, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Oct 2026
Piracetam was the first compound classified as a 'nootropic' by Dr. Corneliu Giurgea in 1972. Proposed mechanisms include membrane fluidity, AMPA receptors and cholinergic transmission.
An older meta-analysis reported global improvement in cognitive impairment, but a 2024 meta-analysis could not establish any memory effect. It has decades of safety data. The reviewed evidence does not establish that routinely adding a choline source improves cognition or prevents headaches with this product.
Different choline sources and patient groups cannot be treated as interchangeable.
Positive allosteric modulator of AMPA receptors
Improves neuronal membrane flexibility
Increases acetylcholine activity
How Piracetam works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Well-studied population; may see greatest benefits
Piracetam is cleared unchanged by the kidneys; reduce dose in mild-to-moderate impairment and avoid in severe impairment
Piracetam has antiplatelet activity and may add to the effects of warfarin, antiplatelet agents, or other anticoagulants, increasing bleeding risk — monitor
Tip: Do not automatically add choline to treat a suspected adverse effect. New or persistent symptoms need assessment, with urgency determined by the symptoms.
Tip: Avoid evening doses
Piracetam has an evidence score of 4.5/10 — emerging evidence based on 108 indexed studies, including 9 meta-analyses. First-ever nootropic (1972), with decades of safety data. Recent meta-analyses find no clear cognitive benefit, including in adults with memory impairment. Representative study: PMID 29502274.
The commonly studied dose of Piracetam is 1200-4800mg daily in divided doses. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Piracetam is in split doses through the day. Taking it with food is preferred. Piracetam is the prototypical racetam nootropic that modulates AMPA receptors and enhances membrane fluidity.
Piracetam is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are headache, insomnia. Use caution if any of these apply to you: Severe kidney impairment (excreted renally); Huntington's disease (theoretical concern).
Huperzine A
Too few graded studiesAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Phosphatidylserine
Too few graded studiesKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Multivitamin
Too few graded studiesNutritional insurance that fills micronutrient gaps. In the large COSMOS trial, a daily multivitamin improved memory and slowed cognitive decline in older adults — but it did not reduce total cancer, cardiovascular disease, or mortality.
Caffeine
Probably helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed May 2026 · evidence from 108 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research